Overview
- Variant Bio introduced Inference, described as the first agentic genomic drug-discovery platform that uses LLM-driven autonomous agents to execute complex analyses.
- The company announced a multi-year research and license agreement with Boehringer Ingelheim for cardiorenal and kidney disease, with potential payments exceeding $120 million.
- Inference consolidates proprietary and public human genomic and multi-omic datasets and has processed hundreds of billions of genetic associations across tens of thousands of studies.
- The platform is now available to research partners, with Variant Bio reporting collaborations with multiple pharmaceutical companies totaling more than $200 million.
- Built over seven years with more than $100 million invested, the platform supports MCP-based integration with tools such as Claude and ChatGPT and operates under a benefit-sharing pledge for contributing communities.